Onco Wiki / Regimen
Brentuximab vedotin + CHP (BV-CHP), adult source-specific reference
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
Wissensdatenbank für Audit. Vorläufiger klinischer Inhalt: Dies ist kein Rezept. Ein Onkologe muss Originalquellen, Anwendbarkeit und Überprüfungsstatus überprüfen. Vollständige Regeln und Einschränkungen sind in der YAML.
Quelle YAML: Vollständige Aufzeichnung
Anmerkungen
Neuropathy modifications preserve separate US adult 1.8 mg/kg every-3-week chemotherapy and eviQ 4038 v3 rules. They are clinician reference text, not automatic dose decisions or baseline eligibility approval; other schedules, monotherapy and pediatric rules are distinct. The US label does not require the eviQ recovery delay in the same row. Histology-specific benefit, regional approval and other dosing/eligibility context require separate review.
Evidence for specific statements
These citations cover only the statements and scopes shown. They do not establish clinical approval of this record.
BV-CHP monitoring follows its own 21-day regimen and drug-specific toxicity assessment. It must not inherit CD20-positive DLBCL, double-hit, IPI, CNS-IPI or anti-CD20-specific checkpoints from R-CHOP. Neuropathy assessment concerns brentuximab vedotin, not vincristine.
Regimen-specific monitoring only; not whole-record dosing, efficacy, eligibility, transplant or clinical approval.
SRC-EVIQ-BV-CHP-4038
eviQ 4038 Treatment schedule, Clinical information, Dose modifications/Haematological toxicity and Pre-treatment assessment.
For adults with previously untreated PTCL receiving ADCETRIS plus CHP, the US label specifies primary G-CSF prophylaxis beginning with Cycle 1. eviQ 4038 instead describes use at clinician discretion and secondary support after ANC-related delay. Check applicable product information and local policy; fever or suspected infection remains urgent despite prophylaxis.
Primary G-CSF with adult previously untreated PTCL/BV-CHP only; not monotherapy, all brentuximab regimens or individualized administration timing.
SRC-ADCETRIS-US-LABEL SRC-EVIQ-BV-CHP-4038
US ADCETRIS label sections 2.4 and 5.3; eviQ 4038 schedule note, growth-factor section and haematological toxicity.
Verwendet von
Contraindications
CI-BRENTUXIMAB-BLEOMYCIN - CI-BRENTUXIMAB-BLEOMYCIN
Anwendungsgebiet
Überwachung
MON-CHP-BV-REGIMEN - MON-CHP-BV-REGIMEN
Unterstützungspflege
SUP-IVIG-HYPOGAMMA - IVIG-Ersatz für Hypogammaglobulinämie